Who is sponsoring NCT03857412?

NCT03857412 is sponsored by Prim. Prof. Dr. Oliver Findl, MBA.

What drugs are being tested in NCT03857412?

Interventions in NCT03857412: Capsular polishing, Non capsular polishing.

What condition does NCT03857412 study?

NCT03857412 studies Posterior Capsule Opacification.

Is NCT03857412 still recruiting?

NCT03857412 is currently status unknown. Last updated 16 March 2020.

Last reviewed 2020-03-16 · How we verify

NCT03857412

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Posterior Capsule Opacification After Lens Capsule Polishing

Status unknown NA Last updated 16 March 2020

What this trial tests

NA trial testing Capsular polishing in Posterior Capsule Opacification in 40 participants. Status unknown.

Timeline

13 February 2019

Primary endpoint
1 May 2020

1 February 2021

Quick facts

Lead sponsor	Prim. Prof. Dr. Oliver Findl, MBA
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	40
Start date	13 February 2019
Primary completion	1 May 2020
Estimated completion	1 February 2021
Sites	1 location across Austria

Drugs / interventions tested

Capsular polishing
Non capsular polishing

Conditions studied

Posterior Capsule Opacification — all drugs for Posterior Capsule Opacification →

Sponsor

Prim. Prof. Dr. Oliver Findl, MBA

Who can join

Adults 21 to 105, any sex, with Posterior Capsule Opacification. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigate the effect of polishing of the lens capsule during cataract surgery on the development of posterior capsule opacification

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Prim. Prof. Dr. Oliver Findl, MBA trials

Trials by the same sponsor.

NCT07425626 — Brillouin Scanning in Cataractous Eyes · active not recruiting
NCT06624826 — Visual Performance of an Extended Depth of Focus IOL in an Emmetropic or Monovision Modality · NA · recruiting
NCT06459284 — Instrument Tissue Interaction at the Grasp Site During Membrane Peeling of Epiretinal Membranes · completed
NCT06948851 — New Postoperative Intraretinal Cystoid Changes After Vitrectomy With Membrane Peeling Due to Epiretinal Membranes · active not recruiting
NCT07436247 — Pseudophakic Eyes With Presbyopia-correcting IOLs: OCT Biometry and Pyramid Aberrometry · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03857412 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prim. Prof. Dr. Oliver Findl, MBA
Last refreshed: 16 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03857412.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing